Market News

Is Keryx Biopharmaceuticals, Inc. (KERX) Stock a Sell after Scott Holmes’s Insider Deal?; Shorts at Zayo Group Holdings (ZAYO) Raised By 17.51%

Zayo Group Holdings, Inc. (NYSE:ZAYO) Logo

Zayo Group Holdings Inc (NYSE:ZAYO) had an increase of 17.51% in short interest. ZAYO’s SI was 15.41 million shares in May as released by FINRA. Its up 17.51% from 13.12M shares previously. With 2.49 million avg volume, 6 days are for Zayo Group Holdings Inc (NYSE:ZAYO)’s short sellers to cover ZAYO’s short positions. The SI to Zayo Group Holdings Inc’s float is 7.97%. The stock increased 0.18% or $0.06 during the last trading session, reaching $33.56. About 2.93 million shares traded or 16.45% up from the average. Zayo Group Holdings, Inc. (NYSE:ZAYO) has risen 0.96% since May 17, 2017 and is uptrending. It has underperformed by 10.59% the S&P500.

Analysts await Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) to report earnings on July, 26. They expect $-0.17 earnings per share, up 19.05% or $0.04 from last year’s $-0.21 per share. After $-0.18 actual earnings per share reported by Keryx Biopharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -5.56% EPS growth.

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. The company has market cap of $699.77 million. It markets its lead product Auryxia , an orally available, absorbable, iron medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. It currently has negative earnings. The firm has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan.

Since January 5, 2018, it had 0 insider purchases, and 17 insider sales for $288,199 activity. 2,830 Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) shares with value of $13,612 were sold by Holmes Scott A. On Monday, January 29 Neylan John F. sold $7,412 worth of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) or 1,541 shares. Adams Brian sold $3,532 worth of stock. Carberry Christine A. sold 2,026 shares worth $9,786. 1,067 shares valued at $5,004 were sold by Madison Greg on Friday, January 5.

Another recent and important Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) news was published by which published an article titled: “Keryx Biopharmaceuticals Announces First Quarter 2018 Financial Results” on May 10, 2018.

Among 15 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. Keryx Biopharmaceuticals has $18 highest and $1.80 lowest target. $8.72’s average target is 50.09% above currents $5.81 stock price. Keryx Biopharmaceuticals had 37 analyst reports since July 23, 2015 according to SRatingsIntel. On Tuesday, August 2 the stock rating was maintained by Ladenburg Thalmann with “Buy”. The stock has “Neutral” rating by JP Morgan on Friday, February 26. The rating was maintained by Morgan Stanley with “Equal-Weight” on Thursday, February 8. The company was maintained on Thursday, August 6 by Maxim Group. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has “Outperform” rating given on Friday, February 26 by Raymond James. Morgan Stanley initiated Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) on Thursday, August 13 with “Underweight” rating. The stock has “Buy” rating by TH Capital on Thursday, July 23. The rating was upgraded by Citigroup on Wednesday, January 11 to “Neutral”. Maxim Group upgraded the stock to “Buy” rating in Wednesday, November 9 report. The firm has “Hold” rating given on Wednesday, November 8 by Stifel Nicolaus.

Investors sentiment decreased to 1.02 in Q4 2017. Its down 0.48, from 1.5 in 2017Q3. It worsened, as 20 investors sold Keryx Biopharmaceuticals, Inc. shares while 32 reduced holdings. 20 funds opened positions while 33 raised stakes. 74.81 million shares or 1.05% less from 75.60 million shares in 2017Q3 were reported. Moreover, First Tru Advsr Lp has 0% invested in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) for 160,992 shares. Boston Prtn holds 0% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) for 409,051 shares. Rhumbline Advisers has 84,306 shares for 0% of their portfolio. Raymond James Associate owns 15,387 shares. Deutsche National Bank Ag owns 205,933 shares. 15,000 are held by Hl Fincl Services Limited Liability Company. First Republic Invest Mngmt accumulated 24,187 shares or 0% of the stock. Teacher Retirement Sys Of Texas invested in 0% or 30,513 shares. Shufro Rose And Lc owns 67,800 shares. Northern Tru reported 0% stake. Aqr Lc owns 28,069 shares. State Street reported 5.80M shares. Balyasny Asset Mgmt Ltd Liability Company stated it has 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Goldman Sachs Group Inc has 0% invested in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Legal General Grp Public Ltd invested in 0% or 31,209 shares.

The stock decreased 0.17% or $0.01 during the last trading session, reaching $5.81. About 1.65 million shares traded or 41.44% up from the average. Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has declined 32.44% since May 17, 2017 and is downtrending. It has underperformed by 43.99% the S&P500.

In a legal document which was filled with the Security Exchange Commission, it was disclosed that the Chief Financial Officer of Keryx Biopharmaceuticals Inc Scott Holmes, an insider in question, made a transaction for 1,158 shares of the public firm, valued at near $6,589 U.S Dollars using the average stock price of $5.7 U.S Dollars. This is not his first insider trade, in the last 30 days, he unloaded another 2,407 shares worth $11,241 USD. The probability of this sell staying a secret is nil because it’s new, with the Chief Financial Officer now having ownership of 168,904 shares — that is 0.14% of Keryx Biopharmaceuticals Inc’s market cap.

More notable recent Zayo Group Holdings, Inc. (NYSE:ZAYO) news were published by: which released: “Global Business Process Outsourcing Company Selects Zayo” on May 17, 2018, also with their article: “Zayo Group COO resigns; REIT conversion idea advances” published on May 03, 2018, published: “Zayo Group 2018 Q3 – Results – Earnings Call Slides” on May 03, 2018. More interesting news about Zayo Group Holdings, Inc. (NYSE:ZAYO) were released by: and their article: “Earnings Preview For Zayo Group Holdings” published on May 03, 2018 as well as‘s news article titled: “Zayo Executives to Present at May Investor Conferences” with publication date: May 14, 2018.

Zayo Group Holdings, Inc., through its subsidiaries, provides bandwidth infrastructure solutions for the communications industry in the United States, Canada, and Europe. The company has market cap of $8.34 billion. The firm operates in six divisions: Fiber Solutions, Transport, Enterprise Networks, Zayo Colocation , Allstream, and Other. It has a 97.28 P/E ratio. The Fiber Solutions segment provides dark fiber, and fiber-to-the-tower and small cell mobile infrastructure services for carriers and other communication service providers, Internet service providers, wireless service providers, media and content companies, large enterprises, and other companies.

Among 21 analysts covering Zayo Group Holdings (NYSE:ZAYO), 16 have Buy rating, 1 Sell and 4 Hold. Therefore 76% are positive. Zayo Group Holdings had 46 analyst reports since August 5, 2015 according to SRatingsIntel. The firm earned “Overweight” rating on Monday, September 21 by JP Morgan. SunTrust maintained the shares of ZAYO in report on Wednesday, December 6 with “Buy” rating. The company was maintained on Tuesday, August 22 by Stifel Nicolaus. As per Tuesday, December 13, the company rating was initiated by SunTrust. Raymond James maintained it with “Strong Buy” rating and $34 target in Monday, September 21 report. The stock has “Neutral” rating by Moffett Nathanson on Wednesday, August 5. On Thursday, December 1 the stock rating was maintained by RBC Capital Markets with “Outperform”. The stock has “Overweight” rating by Barclays Capital on Monday, September 21. The firm earned “Equal-Weight” rating on Wednesday, December 14 by Morgan Stanley. The stock of Zayo Group Holdings, Inc. (NYSE:ZAYO) earned “Outperform” rating by Oppenheimer on Tuesday, August 30.

Investors sentiment increased to 1.32 in 2017 Q4. Its up 0.12, from 1.2 in 2017Q3. It increased, as 29 investors sold Zayo Group Holdings, Inc. shares while 78 reduced holdings. 51 funds opened positions while 90 raised stakes. 207.53 million shares or 2.30% more from 202.87 million shares in 2017Q3 were reported. Avenir Corporation reported 1.50 million shares. Barclays Public Ltd Liability Corporation holds 0.02% or 608,917 shares in its portfolio. Vanguard Grp Inc Inc reported 17.84 million shares. Fmr Ltd Limited Liability Company stated it has 3.84M shares. Toronto Dominion Fincl Bank holds 0% or 10,895 shares in its portfolio. Citadel Advsr reported 2.16M shares. Moreover, Gilder Gagnon Howe & Co Ltd Com has 0% invested in Zayo Group Holdings, Inc. (NYSE:ZAYO) for 7,504 shares. Amp Investors stated it has 0.01% in Zayo Group Holdings, Inc. (NYSE:ZAYO). Uss Mngmt Limited has 1.29% invested in Zayo Group Holdings, Inc. (NYSE:ZAYO) for 3.00M shares. Royal Commercial Bank Of Canada accumulated 337,062 shares or 0.01% of the stock. Reinhart Prns owns 376,230 shares. 62,150 are owned by Gulf Intll State Bank (Uk) Limited. Ckw Grp Inc reported 1,100 shares. Beach Point Cap L P invested 4.26% in Zayo Group Holdings, Inc. (NYSE:ZAYO). Marshall Wace Llp invested in 169,779 shares or 0.26% of the stock.

Since December 29, 2017, it had 0 buys, and 23 selling transactions for $221.35 million activity. Caruso Daniel also sold $4.55 million worth of Zayo Group Holdings, Inc. (NYSE:ZAYO) shares. The insider Steinfort Matt sold $81,150. On Friday, December 29 the insider Richardson Nina sold $24,078. The insider Crouch Andrew sold 14,356 shares worth $510,499. 4.68 million shares valued at $173.21M were sold by GTCR FUND X/A LP on Monday, March 12. The insider Connor Richard W. sold $40,105. Another trade for 10,711 shares valued at $387,096 was sold by Waters John F Jr..

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *